10x Genomics Inc [NASDAQ: TXG] gained 5.36% or 0.48 points to close at $9.34 with a heavy trading volume of 4306641 shares.
The daily chart for TXG points out that the company has recorded -34.77% loss over the past six months.
If we look at the average trading volume of 3.57M shares, TXG reached to a volume of 4306641 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about 10x Genomics Inc [TXG]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TXG shares is $12.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TXG stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for 10x Genomics Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 13, 2025. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on September 03, 2024, representing the official price target for 10x Genomics Inc stock. Previously, the target price had yet another raise to $24, while Jefferies analysts kept a Buy rating on TXG stock. On July 18, 2024, analysts decreased their price target for TXG shares from 40 to 20.
The Average True Range (ATR) for 10x Genomics Inc is set at 0.60, with the Price to Sales ratio for TXG stock in the period of the last 12 months amounting to 1.87. The Price to Book ratio for the last quarter was 1.63, with the Price to Cash per share for the same quarter was set at 3.42. Price to Free Cash Flow for TXG in the course of the last twelve months was 25.69 with Quick ratio for the last quarter at 4.68.
Trading performance analysis for TXG stock
10x Genomics Inc [TXG] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.20. With this latest performance, TXG shares gained by 11.40% in over the last four-week period, additionally sinking by -34.77% over the last 6 months – not to mention a drop of -58.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXG stock in for the last two-week period is set at 56.36, with the RSI for the last a single of trading hit 60.06, and the three-weeks RSI is set at 53.18 for 10x Genomics Inc [TXG]. The present Moving Average for the last 50 days of trading for this stock 8.65, while it was recorded at 8.70 for the last single week of trading, and 14.45 for the last 200 days.
10x Genomics Inc [TXG]: A deeper dive into fundamental analysis
10x Genomics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.68 and a Current Ratio set at 5.37.
10x Genomics Inc [TXG]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXG. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for 10x Genomics Inc go to 24.59%.
An analysis of Institutional ownership at 10x Genomics Inc [TXG]
The top three institutional holders of TXG stocks are: FMR LLC with ownership of 13.01 million shares, which is approximately 10.836%. VANGUARD GROUP INC, holding 10.19 million shares of the stock with an approximate value of $$198.18 million in TXG stocks shares; and VANGUARD GROUP INC, currently with $$181.15 million in TXG stock with ownership which is approximately 7.7571%.
